Results 201 to 210 of about 89,290 (238)

Demonstration of bactericidal and synergistic activity of quercetin with meropenem among pathogenic carbapenem resistant Escherichia coli and Klebsiella pneumoniae.

Microbial Pathogenesis, 2020
Rapid dissemination of carbapenem resistant Enterobacteriaceae (CRE) is considered to be a global issue. Quercetin is a well known antimicrobial agent. Hence, it would be important to investigate bactericidal and synergistic interaction of quercetin with
A. Pal, A. Tripathi
semanticscholar   +1 more source

Meropenem / Meropenem-vaborbactam

2017
Meropenem is a broad-spectrum parenteral carbapenem with antimicrobial activity against a wide range of Gramnegative and Gram-positive bacteria, including anaerobes. As a consequence of emerging multidrug resistance, especially in Gram-negative organisms, the clinical reliance on meropenem and other carbapenems increased after their introduction ...
Peleg, A. Y., Harris, P.
openaire   +2 more sources

In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.

Journal of Antimicrobial Chemotherapy, 2020
OBJECTIVES To evaluate in vitro activity of the novel β-lactamase boronate inhibitor taniborbactam (VNRX-5133) combined with cefepime or meropenem against 500 urinary Gram-negative bacilli.
Xiaojuan Wang, Chun-jiang Zhao, Qi Wang, Zhan-wei Wang, Xinyue Liang, Fei-fei Zhang, Yawei Zhang, Han Meng, Hongbin Chen, Shuguang Li, Chengcheng Zhou, Henan Li, Hui Wang   +12 more
semanticscholar   +1 more source

Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples.

Therapeutic Drug Monitoring, 2020
BACKGROUND The mortality rate of patients with a drug-resistant bacterial infection is high, as are the associated treatment costs. To overcome these issues, optimization of the available therapeutic options is required.
Mohammad Alshaer, W. Alghamdi, E. Graham, C. Peloquin   +3 more
semanticscholar   +1 more source

Meropenem

Reactions Weekly, 2022
  +5 more sources

Meropenem

Reactions Weekly, 2016
  +4 more sources

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Lancet. Infectious Diseases (Print), 2018
M. Paul, G. Daikos, E. Durante-Mangoni, D. Yahav, Y. Carmeli, Yael Dishon Benattar, A. Skiada, Roberto Andini, N. Eliakim‐Raz, A. Nutman, O. Zusman, A. Antoniadou, P. Pafundi, A. Adler, Y. Dickstein, I. Pavleas, R. Zampino, Vered Daitch, R. Bitterman, H. Zayyad, Fidi Koppel, Inbar Levi, T. Babich, L. Friberg, J. Mouton, U. Theuretzbacher, L. Leibovici   +26 more
semanticscholar   +1 more source

Meropenem

Reactions Weekly, 2020
  +4 more sources

MEROPENEM

The Pediatric Infectious Disease Journal, 1998
openaire   +2 more sources

Meropenem

Reactions Weekly, 2015
openaire   +2 more sources